Novel Strategy for Three-Dimensional Fragment-Based Lead Discovery

被引:17
|
作者
Yuan, Haoliang [1 ]
Lu, Tao [1 ]
Ran, Ting [1 ]
Liu, Haichun [1 ]
Lu, Shuai [1 ]
Tai, Wenting [1 ]
Leng, Ying [1 ]
Zhang, Weiwei [1 ]
Wang, Jian [1 ]
Chen, Yadong [1 ]
机构
[1] China Pharmaceut Univ, Lab Mol Design & Drug Discovery, Sch Basic Sci, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
DEPENDENT KINASE INHIBITORS; STRUCTURE-GUIDED DESIGN; HIGH-AFFINITY LIGANDS; C-MET INHIBITORS; DRUG DESIGN; CDK2; INHIBITORS; ANILINO PYRIMIDINES; SELECTIVE CLASS; BINDING MODE; POTENT;
D O I
10.1021/ci200003c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug design (FBDD) is considered a promising approach in lead discovery. However, for a practical application of this approach, problems remain to be solved. Hence, a novel practical strategy for three-dimensional lead discovery is presented in this work Diverse fragments with spatial positions and orientations retained in separately adjacent regions were generated by deconstructing well-aligned known inhibitors in the same target active site. These three-dimensional fragments retained their original binding modes in the process of new molecule construction by fragment linking and merging. Root-mean-square deviation (rmsd) values were used to evaluate the conformational changes of the component fragments in the final compounds and to identify the potential leads as the main criteria. Furthermore, the successful validation of our strategy is presented on the basis of two relevant tumor targets (CDK2 and c-Met), demonstrating the potential of our strategy to facilitate lead discovery against some drug targets.
引用
收藏
页码:959 / 974
页数:16
相关论文
共 50 条
  • [1] A rule of three for fragment-based lead discovery?
    Congreve, M
    Carr, R
    Murray, C
    Jhoti, H
    DRUG DISCOVERY TODAY, 2003, 8 (19) : 876 - 877
  • [2] Fragment-based lead discovery
    David C. Rees
    Miles Congreve,
    Christopher W. Murray
    Robin Carr
    Nature Reviews Drug Discovery, 2004, 3 : 660 - 672
  • [3] Fragment-Based Lead Discovery
    Davis, Ben J.
    Roughley, Stephen D.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 50: PLATFORM TECHNOLOGIES IN DRUG DISCOVERY AND VALIDATION, 2017, 50 : 371 - 439
  • [4] Fragment-Based Lead Discovery
    Congreve, Miles
    Murray, Christopher W.
    Carr, Robin
    Rees, David C.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 42, 2007, 42 : 431 - 448
  • [5] Fragment-based lead discovery
    Rees, DC
    Congreve, M
    Murray, CW
    Carr, R
    NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 660 - 672
  • [6] Fragment-based lead discovery and optimization using the SHAPES strategy
    Lepre, CA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2762 - U2762
  • [7] Fragment-Based Lead Discovery and Design
    Joseph-McCarthy, Diane
    Campbell, Arthur J.
    Kern, Gunther
    Moustakas, Demetri
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2014, 54 (03) : 693 - 704
  • [8] EXPERIENCES IN FRAGMENT-BASED LEAD DISCOVERY
    Hubbard, Roderick E.
    Murray, James B.
    FRAGMENT-BASED DRUG DESIGN: TOOLS, PRACTICAL APPROACHES, AND EXAMPLES, 2011, 493 : 509 - 531
  • [9] Fragment-based lead discovery grows up
    Monya Baker
    Nature Reviews Drug Discovery, 2013, 12 : 5 - 7
  • [10] Fragment-based lead discovery: leads by design
    Carr, RAE
    Congreve, M
    Murray, CW
    Rees, DC
    DRUG DISCOVERY TODAY, 2005, 10 (14) : 987 - 992